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http://www.biomedcentral.com/1746-6148/10/111RESEARCH ARTICLE Open AccessIdentification of serum biomarkers in dogs
naturally infected with Babesia canis canis using
a proteomic approach
Josipa Kuleš1, Vladimir Mrljak2, Renata Barić Rafaj1, Jelena Selanec2, Richard Burchmore3 and Peter D Eckersall3*Abstract
Background: Canine babesiosis is a tick-borne disease that is caused by the haemoprotozoan parasites of the
genus Babesia. There are limited data on serum proteomics in dogs, and none of the effect of babesiosis on the
serum proteome. The aim of this study was to identify the potential serum biomarkers of babesiosis using
proteomic techniques in order to increase our understanding about disease pathogenesis.
Results: Serum samples were collected from 25 dogs of various breeds and sex with naturally occurring babesiosis
caused by B. canis canis. Blood was collected on the day of admission (day 0), and subsequently on the 1st and 6th
day of treatment.
Two-dimensional electrophoresis (2DE) of pooled serum samples of dogs with naturally occurring babesiosis (day 0,
day 1 and day 6) and healthy dogs were run in triplicate. 2DE image analysis showed 64 differentially expressed
spots with p≤ 0.05 and 49 spots with fold change ≥2. Six selected spots were excised manually and subjected to
trypsin digest prior to identification by electrospray ionisation mass spectrometry on an Amazon ion trap tandem
mass spectrometry (MS/MS). Mass spectrometry data was processed using Data Analysis software and the
automated Matrix Science Mascot Daemon server. Protein identifications were assigned using the Mascot search
engine to interrogate protein sequences in the NCBI Genbank database.
A number of differentially expressed serum proteins involved in inflammation mediated acute phase response,
complement and coagulation cascades, apolipoproteins and vitamin D metabolism pathway were identified in
dogs with babesiosis.
Conclusions: Our findings confirmed two dominant pathogenic mechanisms of babesiosis, haemolysis and acute
phase response. These results may provide possible serum biomarker candidates for clinical monitoring of
babesiosis and this study could serve as the basis for further proteomic investigations in canine babesiosis.
Keywords: Dog, Babesiosis, Acute phase proteins, Serum biomarkers, Proteomics, 2-dimensional electrophoresisBackground
Canine babesiosis is a tick-borne disease that is caused by
the haemoprotozoan parasites of the genus Babesia [1].
Babesia is one of the most ubiquitous and widespread
blood parasite in the world based on number and distribu-
tion of species in animals. It can be compared with the
Plasmodium, with which it shares phylogenetic proximity
and numerous biological features. There are three antigen-
ically different subspecies of Babesia canis: B. canis canis,* Correspondence: David.Eckersall@glasgow.ac.uk
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unless otherwise stated.B. canis vogeli and B. canis rossi [2,3]. Canine babesiosis
caused by B. canis canis is a very common cause of mor-
bidity of dogs in Croatia [4-7].
The typical signs of uncomplicated babesiosis are pale
mucous membranes, fever, anorexia, depression, spleno-
megaly and water hammer pulse. The clinical manifestation
of the complicated form is variable and includes acute renal
failure, cerebral babesiosis, coagulopathy, icterus and hepa-
topathy, immune-mediated haemolytic anaemia (IMHA),
peracute babesiosis, acute respiratory distress syndrome
(ARDS), haemoconcentration and shock [8]. Much of the
disease process in babesiosis could be explained by the host
inflammatory response to the parasite, rather than thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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response and activation of coagulation system. The patho-
logical mechanisms include endothelial cell activation and
damage, vascular permeability increase, tissue hipoxia, ab-
normal perfusion and leukocyte infiltration. These could
lead to microcirculation blockade, disseminated intravas-
cular coagulation, and, in severe cases, to systemic inflam-
matory response syndrome (SIRS) and multiple organ
dysfunction syndrome (MODS).
Proteomics has become one of the most significant post-
genomic era tools due to advances in proteomic tech-
nologies which have allowed an extended experimental
approach to investigation of biological systems. The use of
proteomic methods in animal sciences can help researchers
to identify key proteins and their changed expression in re-
sponse to different experimental conditions. In a general
sense, the research field of host-pathogen interactions is
very important due to its impact and importance of infec-
tious diseases that threaten human and animal health. Nat-
urally occurring animal diseases can be studied to improve
the health of animals which in turn may lead to improve-
ments in the characterization, clinical management and
treatment of human diseases through comparative medi-
cines [9]. There are limited data on serum proteomics in
dogs [10], and none on babesiosis.
The aim of this study was to identify potential serum
biomarkers using proteomic techniques and to increase
our understanding about disease pathogenesis.
Methods
Sample collection
Serum samples were collected from 25 dogs of various
breeds and sex with naturally occurring babesiosis caused
by B. canis canis, admitted to Clinic for Internal Diseases,
Faculty of Veterinary Medicine, University of Zagreb,
Croatia. This study was approved by the Committee on the
Ethics of the University of Zagreb, Faculty of Veterinary
Medicine (Permit Number: 640-01/06-17/30; 61-01/139-
06-03), and informed owner consent was granted in each
case. There were 8 females and 17 males, aged from
2 months to 10 years (average age 3 years and 1 month).
Eleven dogs were mixed breed, 5 were Labrador Retriever,
2 were Croatian Sheepdog, and one dog of Golden
Retriever, American Staffordshire Terrier, German Shepard,
Doberman, Alpine Dachsbracke and Alaskan Malamute.
Blood was collected on the day of admission (day 0, labeled
as B0), and subsequently on the 1st (day 1, B1) and 6th day
(day 6, B6) of treatment. The diagnosis of babesiosis was
confirmed by demonstration of the parasites within the in-
fected erythrocytes in thin blood smears stained with May-
Grünwald-Giemsa stain. Subspecies were confirmed using
PCR (polymerase chain reaction). One dose (6 mg/kg) of
imidocarb dipropionat (Imizol® 12%, Schering-Plough) was
administered to all the dogs subcutaneously on the day ofadmission. All dogs survived and successfully recovered
from disease. Serum was also collected from 10 healthy
dogs and they were control group (labeled as C). These
dogs were considered healthy based on physical examin-
ation and haematological and biochemical data. All dogs
were mixed breed, aged from 2 to 10 years, 6 of them were
males and 4 females.
Two-dimensional electrophoresis (2DE) and 2DE analysis
Serum samples were pooled into 4 groups (day 0, day
1, day 6 and control). For making the pool, equal
amount of serum was used from each animal. The pro-
tein concentrations of the serum samples were mea-
sured using the Bradford assay (Bio-Rad Laboratories,
Inc., Redmond, WA, USA). Sera from each pool were
suspended in rehydration buffer (8 M urea, 2%
CHAPS, 0.001% bromophenol blue, 45 mM DTT, 0.2%
Bio-lyte pH 3–10) in order to archive final protein con-
centration of 200 μg/μl. 200 μl of sample was loaded
onto a 11 cm IPG strip (immobilized pH gradient,
pH 3–10, linear, Biorad Ltd, Hemel Hempstead UK).
Isoelectric focusing was performed (Protean IEF Cell,
Biorad Ltd, Hemel Hempstead UK) with combined re-
hydration and focusing step carried out over 17 h with
a total of 35,000 V-h. Then the IPG strips were first
equilibrated for 10 min in equilibration buffer 1 (6 M
urea, 0.375 M Tris–HCl pH 8.8, 20% glycerol, 2% SDS,
2% DTT) and subsequently in equilibration buffer 2
(6 M urea, 0.375 M Tris–HCl pH 8.8, 20% glycerol, 2%
SDS, 2.5% iodoacetoamide) for 10 min. Electrophoresis
in the second dimension was carried out using Criterion
precast gels (XT Bis-Tris Gel, 4-12% polyacrylamide gel,
IPG + 1 well, 11 cm IPG strip; Bio-Rad) at 200 V for 45–
50 minutes. 2DE gels were then stained with colloidal
Coomassie blue G250 (0.12% G250, 20% v/v methanol,
10% v/v o-phosphoric acid, 10% w/v ammonium sulphate)
and destained in 5% v/v acetic acid. Molecular mass and
pI values were estimated by running a sample containing
serum proteins together with a mixture of protein stan-
dards (Bio-Rad). Each pool was analyzed in triplicate.
The stained gels were scanned (UMAX PowerlookIII,
USA) and digitized images of gels were analyzed
using the Progenesis Same Spot software (Nonlinear
Dynamics Ltd, Newcastle, UK) to identify protein
spots which were differentially expressed through
time (power >0.8 and ANOVA significance score of <0.05
between experimental groups).
Trypsin digestion and MS analysis
The selected spots were manually excised from each gel
and destained for 30 min using 0.5 ml 100 mM ammo-
nium bicarbonate and then with 50% acetonitrile/100 mM
ammonium until gel pieces were transparent. The gels
were dehydrated for 10 min with acetonitrile (100%) and
Kuleš et al. BMC Veterinary Research 2014, 10:111 Page 3 of 10
http://www.biomedcentral.com/1746-6148/10/111dried for 30 min using a Speed-Vac system. To prepare
trypsin solution, 25 mM ammonium bicarbonate was
added to trypsin (sequencing grade modified Porcine
Trypsin, Promega). The trypsin solution (10 μl) was pipet-
ted onto each dried protein spot and incubated overnight
at 37°C. To extract the peptide fragments from the tryptic
digests, 20 μl of 5% (v/v) formic acid were added and incu-
bated for 20 min. Thereafter, 20 μl of acetonitrile was
added to gel pieces and incubated for 20 min. After each
step, the supernatants were pooled and dried using a
Speed-Vac system.
Peptides were solubilized in 0.5% formic acid and frac-
tionated on a nanoflow ultra high-performance liquid chro-
matography (uHPLC) system (Thermo RSLCnano) before
online analysis by electrospray ionisation (ESI) mass spec-
trometry on an Amazon ion trap tandem mass spectrom-
etry (MS/MS) (Bruker Daltonics). Peptide separation was
performed on a Pepmap C18 reversed phase column (LC
Packings), using a 5 - 85% v/v acetonitrile gradient (in
0.5% v/v formic acid) run over 45 min at a flow rate of
0.2 l/min. Mass spectrometry (MS) analysis was performed
using a continuous duty cycle of survey MS scan followed
by up to ten MS/MS analyses of the most abundant pep-
tides, choosing the most intense multiply charged ions
with dynamic exclusion for 120 s.
Protein identification
MS data was processed using Data Analysis software
(Bruker) and the automated Matrix Science Mascot
Daemon server (v2.1.06). Protein identifications were
assigned using the Mascot search engine to interrogate
protein sequences in the NCBI Genbank database,
allowing a mass tolerance of 0.4 Da for both MS and
MS/MS analyses. All known contaminants (trypsin auto
proteolysis and known keratin peaks) were excluded dur-
ing the process. Search parameters included mammals as
taxonomy; trypsin as proteolytic enzyme, a missed cleav-
ages up to 1; fixed modification: carbamidomethyl (C);
variable modification: oxidation (M).
APP assays
CRP and haptoglobin levels were determined using an
automated analyser Pentra 400 (Horiba UK Ltd,
Northampton, UK) using established methods (Reactiv-
Lab, Avacta Animal Health, Wetherby, UK) as described
in Gow et al. [11] and Crawford et al. [12]. The canine
CRP assay is an immunoturbidimetric assay. Briefly,
formed antibody-antigen complex is measured turbidimet-
rically by the spectrophotometer, and the absorbance is
directly proportional to the amount of CRP present in the
serum sample [11]. Haptoglobin was assayed with a bio-
chemical assay in which a sample of serum is incubated
with haemoglobin in addition of activator to form an Hp-
Hb complex [12]. The pH is then reduced by addition ofreagent which destroys the peroxidase activity of Hb, ex-
cept for the Hb molecules bound to Hp. The preservation
of the peroxidase activity of the Hb is directly proportional
to the amount of Hp present in the sample [12].
Statistical analysis
Statistical analysis for APP assays were performed using
a statistical computer application Statistica 8 (statistical
software program Statistica 8 for Windows, StatSoft
Inc.). Distribution of data were tested by Kolmogorov-
Smirnov test, and as they were not distributed normally,
the Friedman test was used for comparing multiple
dependent samples, and Mann–Whitney U test to iden-
tify statistically significant differences between healthy
and diseased dogs. Differences with a P-value <0.05
were considered statistically significant.
Results
Proteomic profile of canine babesiosis
2D electrophoresis of pooled serum samples of dogs
with naturally occurring babesiosis (day 0, day 1 and
day 6) and healthy dogs were run in triplicate. 2D
image analysis showed 64 differentially expressed
spots with ANOVA P ≤ 0.05 and 49 spots with fold
change ≥2. In total, there were 37 spots with P ≤ 0.05
and fold change ≥2, with power >0.8 (Figure 1). A
representative gel images for each of the experimental
groups are given in the Figure 2. Six spots were se-
lected for running on mass spectrometry (namely,
spots 596, 579, 432, 590, 869 and 327). Their fold
change and expression level between different experi-
mental groups is given in Table 1. For inclusion in list
criteria were Mascot score higher than 100 and se-
quence coverage over 10%. The summary of identified
proteins is given in the Table 2. Identification of pro-
teins for each experimental group (B0, B1, B6, control)
are presented as Additional files 1, 2, 3 and 4.
APPs in canine babesiosis
Levels of CRP and haptoglobin were determined on day 0,
day 1 and day 6 in serum of dogs with babesiosis and
healthy dogs (Figures 3 and 4). Non-parametric Friedman
test was used to identify statistically significant differences.
CRP was significantly different between each group of in-
fected dogs, as well as compared with healthy dogs, while
haptoglobin showed significant decrease on day 1 of dis-
ease comparing to day 6 and to healthy dogs.
Discussion
Proteomics is a rapidly maturing essential tool in the
“omics” age following the huge success of genomics study.
Studying proteins has been subject of interest for many re-
searchers as any cell responses to stimuli or stress are
manifested by the alteration of protein expression level. In
Figure 1 Reference image 2DE map of differentially expressed spots with marked selected spots. Representative 2-DE map of canine
serum obtained by performing the first dimension (IEF) on IPG strips pH 3–10 and the second dimension on 4–12% gradient SDS-PAGE gels. The
protein spots were visualized by Coomassie blue staining. The indicated spots were excised from gel and identified by MS/MS. Mr standard values
are indicated on the left.
Kuleš et al. BMC Veterinary Research 2014, 10:111 Page 4 of 10
http://www.biomedcentral.com/1746-6148/10/111this study, we used a proteomic approach to analyze the
alterations in canine serum proteome due to B. canis
canis infection. 2DE gels on three replicates generated
from the infected serum samples were compared with
the gels from healthy serum samples, followed by MS/
MS analysis, which revealed several significantly differ-
ential serum proteins. Analytical problems in proteo-
mics are related to the diversity of protein expression
(multiple protein forms) and the dynamic expression
range (protein abundance). In the majority of our selected
spots, multiple proteins were identified per spot due to
similar migration patterns and insufficient resolving
power. Proteins can migrate to multiple spots on 2D gels
for a variety of reasons, including differential proteinFigure 2 Representative images of 2-dimensional electrophoresis gel
treatment, B) dogs with babesiosis on the 1st day after admission, C) dogsprocessing and posttranslational or artefactual modifica-
tions. The protein products from multiple genes also can
run to the same coordinates on a gel. Both differential mi-
gration and comigration of proteins complicate compara-
tive, quantitative pattern analyses of 2D gels [13].
A number of differentially expressed serum proteins in-
volved in inflammation mediated acute phase response,
complement and coagulation cascades, apolipoproteins
and vitamin D metabolism pathway were identified in
dogs with babesiosis. Some proteins in the particular spot
were present in all groups, while others are only in some
of them. All spots, except spot 432, were up-regulated in
diseased dogs while the down-regulation of spot 432 re-
sulted from decreased levels of antithrombin III, vitamins of all experimental groups. A) dogs with babesiosis before
with babesiosis on the 6th day after admission, D) healthy dogs.
Table 1 Protein expression change for each spot between experimental groups
Spot
no.a
P-value
(ANOVA)
Fold
change
Log normalised volume
B0 B1 B6 CONTROL
327 0.004 8.1 5.11 ± 0.63 4.46 ± 0.22 4.4 ± 0.14 4.29 ± 0.11
869 0.010 3.4 3.24 ± 0.3 3.29 ± 0.24 2.92 ± 0.34 2.76 ± 0.2
590 0.010 3.2 3.52 ± 0.21 3.21 ± 0.25 3.11 ± 0.33 3.03 ± 7.00e-002
579 0.019 4.4 5.73 ± 0.4 6.03 ± 0.25 5.59 ± 0.34 5.37 ± 0.33
596 0.019 3.6 5.57 ± 8.59e-002 5.91 ± 0.49 5.43 ± 0.28 5.4 ± 7.71e-002
432 0.020 2.0 4.81 ± 0.11 5.06 ± 0.11 4.92 ± 0.19 5.07 ± 0.19
aNumber refer to protein spots indicated in Figure 1.
Table 2 Protein identification of differentially expressed proteins
Protein name Accession
numbera
Number of
unique peptidesb
Sequence
coverage (%)b
Mascot
scoreb
Biological function Spot no.c
Alpha-1-acid glycoprotein gi|345777714 25 53 628 Acute phase response 596, 579
Apolipoprotein A-I gi|73955106 70 72 1834 Cholesterol, lipid and
steroid metabolism
869, 432
Lipid transport
Antithrombin-III gi|359320010 5 19 161 Blood coagulation 432
Vitamin D-binding protein gi|73975215 24 57 543 Vitamin D metabolic process 432
Apolipoprotein A-IV gi|345799905 66 72 1401 Removal of superoxide radicals 590
Lipid metabolism
Complement C3 gi|359322249 16 15 356 Complement activation
(classical and alternative pathway)
590
Inflammatory response
Serotransferrin gi|73990142 25 40 672 Cellular iron ion homeostasis 327
Iron ion transport
Hemopexin gi|73988725 12 44 273 Cellular iron ion homeostasis 327
Alpha-2-HS-glycoprotein gi|359323766 7 40 273 Acute phase response 596, 432
Haptoglobin gi|123511 5 41 159 Cellular iron ion homeostasis 579
Acute phase response
Alpha-2-antiplasmin gi|345805038 3 13 101 Acute phase response 327
Fibrinolysis
Clusterin gi|50979240 31 25 864 Apoptosis 596, 579
Complement pathway
Leucine-rich-α2-glycoprotein gi|73987375 24 50 625 Acute phase response 432
Zinc-alpha-2-glycoprotein gi|73958037 15 46 310 Immune response 579
Immunoglobulin
gamma heavy chain B
gi|17066526 12 27 206 Immune response 432
Complement activation
Immunoglobulin gamma
heavy chain C
gi|17066528 10 20 222 Immune response 432
IgA heavy chain
constant region
gi|598107 7 22 124 Immune response 327
aAccesion number from NCBI Genbank database for Canis lupus familiaris.
bData are representatives of four separate experimental group.
cNumber refer to protein spots indicated in Figure 1.
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Figure 3 Concentration of CRP in healthy (control) dogs (C),
dogs with babesiosis before treatment (B0), on the 1st day (B1)
and 6th day (B6) after admission.
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comparing to healthy dogs.
In order to access inflammatory status of dogs and ex-
tent of acute phase response, we measured CRP in serum
of dogs. Elevated CRP levels have been reported in dogs
after surgical trauma [14], during infections including
leishmaniasis [15], ehrlichiosis [16], babesiosis [5], lepto-
spirosis [17], bordetellosis [18], parvovirus infection [17]
and pyometra [19], and with noninfectious conditions in-
cluding neoplasia [20], autoimmune disorders [20], acute
pancreatitis [21], inflammatory bowel disease [22] and car-
diac valvular disease [23]. Several researchers have ex-
plored the acute phase response and specifically CRP in
canine babesiosis [5]. In our study in dogs infected with B.
canis canis CRP concentrations were significantly higher
than in healthy dogs and CRP levels decreased with timeFigure 4 Concentration of haptoglobin in healthy (control)
dogs (C), dogs with babesiosis before treatment (B0), on the
1st day (B1) and 6th day (B6) after admission.and treatment. CRP is a biomarker and indicator of in-
flammation, and plays a role of an acute phase reactant in
babesiosis.
Using proteomic approach, we have found increased
expression level of several further acute phase proteins
including alpha-1-acid glycoprotein, leucine-rich-alpha-
2-glycoprotein, hemopexin, serotransferrin and alpha-2-
HS-glycoprotein, in dogs with babesiosis suggesting a
possible association with the disease pathogenesis.
Alpha-1-acid glycoprotein (AGP) is a positive acute
phase reactant in all mammals investigated to date, except
for the pig, with antiinflammatory and immunomodulat-
ing activities [24]. Lobetti et al., [25] found increased levels
of AGP in dogs invaded with B. rossi.
The leucine-rich repeat family of proteins, including
leucine-rich-alpha-2-glycoprotein (LRG), have been shown
to be involved in protein-protein interaction, signal trans-
duction, and cell adhesion and development [26]. LRG was
recently identified as a potential disease activity marker in
Crohn’s disease and rheumatoid arthritis and a novel serum
biomarker for monitoring disease activity during therapy in
autoimmune patients [27,28]. It was hypothesized that
serum LRG would potentially surrogate for CRP.
α2-Heremans–Schmid-(α2-HS) glycoprotein (A2HSG)
is a plasma protein synthesized in liver and enriched in
bone, a homologue of bovine fetuin-A. This protein is a
negative acute-phase protein whereas its level declines fol-
lowing infection, inflammation and malignancy. It plays a
role in augmentation of phagocytosis of neutrophils by
macrophages, thus acting as an anti-inflammatory mol-
ecule [29].
Three APP involved in haemoglobin and iron metabol-
ism and transport, haptoglobin, hemopexin and serotrans-
ferrin, indicate the role of haemolysis in the course of
babesiosis.
Hemopexin, another up-regulated protein in our
study, provides the second line of defense preventing
haemoglobin-mediated oxidative damage during the intra-
vascular haemolysis and heme-bound iron loss [30]. Its
synthesis is induced under inflammatory conditions dur-
ing disease progression, resulting in haemoglobin degrad-
ation and reactive oxygen species (ROS) generation in
parasitized erythrocytes. While hemopexin helps in scav-
enging free heme, the free iron is taken up and trans-
ported by serotransferrin [31]. Haptoglobin was identified
only in dogs with babesiosis on 6th day after treatment.
We determined levels of haptoglobin in serum of all dogs,
in order to achieve better understanding of haemolysis in
babesiosis. In our study, we found significant decrease of
haptoglobin levels on day 1 of disease comparing to day 6
and to healthy dogs. Some authors found increase and
some decrease of haptoglobin during babesiosis [5,32]
suggesting that serum concentration of Hp can be influ-
enced by other factors than acute phase response. In this
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haemoglobin, and the complex is cleared by the reticulo-
endothelial system, resulting in a decrease in serum Hp
concentrations. The release of free haemoglobin into the
vascular system following a haemolytic crisis or the onset
of haemolytic anaemia will therefore cause a marked loss
of haptoglobin. Therefore levels of Hp in dogs with B.
canis canis infection might be the result of an imbalance
between the synthesis and the clearance of this protein
from the circulation, and in particular may relate to the
magnitude of haemolysis. Increase or decrease of Hp levels
depends whether inflammatory or haemolytic component
dominates. The ability rapidly and accurately to measure
Hp levels may be a valuable diagnostic aid, especially in
detecting the magnitude of haemolysis in babesiosis.
Lipid metabolism is of great importance in babesiosis
because of the catabolic reaction within the acute phase
response and because of the fact that the majority of hae-
moparasites (including Babesia) cannot synthesize their
own lipids, so they take them up from host plasma (pre-
dominantly high density lipoproteins (HDL)) [33].
The main protein component of HDL, apolipoprotein A-
I (apoA-I) participates in the reverse transport of choles-
terol from tissues to the liver for excretion by promoting
cholesterol efflux from tissues and by acting as a cofactor
for the lecithin cholesterol acyltransferase (LCAT). ApoA-
1 is known to have anti-inflammatory effects, and thus
apoA-1 increase (spot 869) may contribute to the limita-
tion of inflammatory processes. In humans, this protein be-
longs to negative APP and lowered plasma levels of apoA-I
is considered to be correlated to an increased risk of car-
diovascular diseases and atherosclerosis. The distribution
of plasma lipids and lipoproteins in dogs is quite unlike
that in humans, with dogs having approximately five to six
times as much HDL as LDL [34].
Apolipoprotein A-IV (apo A-IV) (spot 590) is a 46 kDa
protein that circulates freely in blood or associates with
chylomicrons and high-density lipoprotein. Apo A-IV has a
role in radicals catabolism, activation of lipoprotein lipase
by apoC-II and activation of LCAT. It has been proposed
that Apo A-IV plays a protective role against atheroscler-
osis and reverses cholesterol transport [35,36]. Because of
oxidative damage caused by free radicals generated during
the course of babesiosis [37], increased levels of apo A-IV
may have antioxidative activity as an oxidation inhibitor of
lipids and lipoproteins.
A primary consequence of Babesia infections are haemo-
stasis disturbances together with inflammation-related
complications. It has been well documented that interplay
between inflammation and coagulation pathways lead to
activation of both systems [38]. Thrombin generated as a
by-product of the coagulation process can further promote
inflammatory responses [39], while inflammation sup-
presses anticoagulation mechanisms [40].Antithrombin-III (AT III) is a major endogenous anti-
coagulant and antiinflammatory agent. It is a circulating
glycoprotein that can inhibit thrombin directly and via a
number of upstream factors. The AT III levels were sig-
nificantly decreased in dogs with babesiosis (spot 432)
indicating an imbalance in haemostasis defined by the
overproduction of thrombin and fibrin [41]. This could
be a consequence of inhibitor breakdown and/or liver
dysfunction affecting inhibitor production in dogs with
babesiosis. Low AT III levels are likely to be due to in-
creased consumption from thrombin binding in throm-
bin–antithrombin (TAT) complexes.
Alpha-2-antiplasmin is a major inhibitor and regula-
tor of fibrinolysis and one of the essential factors in-
volved in haemostasis. It is a member of the serine
proteinase inhibitor (serpin) family and inhibits proteases
in general, including trypsin, chymotrypsin, plasma kalli-
krein, but its main physiological activity is very rapid in-
hibition of plasmin by forming a stable complex with this
proteinase [42]. Thus, the level of alpha-2-antiplasmin in
circulation may be a crucial determinant of fibrinolysis in
babesiosis.
Complement activation in babesiosis was confirmed by
clusterin and C3 increased expression. Complement com-
ponent 3 (C3) plays a central role in the activation of com-
plement system. Its activation is required for both classical
and alternative complement activation pathways. Clusterin
(CLU, complement lysis inhibitor, apolipoprotein J) is a
heterodimeric glycoprotein produced by a wide array of
tissues and found in most biologic fluids. It participates in
many different biological reactions including regulation of
the terminal complement cascade, lipid transport, initi-
ation of apoptosis, endocrine secretion, promotion of cell
interactions, tissue remodeling, adhesion, membrane pro-
tection [43]. Recently, upregulated expression of CLU has
been reported in tumor pathogenesis and progression,
Alzheimer’s disease, atherosclerosis, renal diseases [44,45].
Vitamin D binding protein, also known as group-
specific component globulin (Gc-globulin), belongs to
the albumin superfamily of binding proteins. One well-
recognized function of vitamin D binding protein is to
act as a carrier protein for vitamin D and its plasma me-
tabolites. Clinical studies and animal models have also
shown its role as an actin-scavenging protein in the vas-
cular and extracellular system [46]. To date, vitamin D
binding protein has been recognized widely as a protein
with markedly decreased concentrations in inflammatory
and necrotic diseases. The extent of the decrease may
have prognostic significance for patient outcomes. Vita-
min D binding protein has other potential roles in re-
sponses to acute tissue injury through conversion to a
macrophage-activating factor, neutrophil chemotactic ac-
tivity, and enhancement of C5a-mediated signaling. Low
vitamin D binding protein concentrations have been
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severe organ damage, such as fulminant hepatic failure,
acetaminophen (paracetamol) overdose, multiple trauma,
and multiple organ failure [47-50]. Several studies have
shown that low vitamin D binding protein concentrations
are associated with a poor prognosis for survival and an
increased risk of developing MODS in sepsis [51]. De-
creased vitamin D binding protein levels in babesiosis can
be consequence of consumption due to haemolysis and in-
creased actin removal.
Our findings confirmed two dominant pathogenic
mechanisms of babesiosis, haemolysis and acute phase
response [52,53]. The role of haemolysis in the course of
babesiosis was demonstrated by haptoglobin, hemopexin
and serotransferrin expression changes. Tissue hypoxia,
which is a common feature in babesiosis, is probably
one of the major causes for the release of cytokines, oxy-
gen free radicals, nitric oxide and other inflammatory
mediators. As a consequence, acute phase response was
triggered and demonstrated throughout wide variety of
acute phase proteins (alpha-1-acid glycoprotein, leucine-
rich-alpha-2-glycoprotein, hemopexin, serotransferrin,
alpha-2-HS-glycoprotein, albumin). Also, release of ROS
and consequent oxidative damage, lead to increased ex-
pression of apolipoproteins (apoA-I and apoA-IV) with
antioxidative activity. Impairment of coagulation and fi-
brinolytic system was demonstrated throughout consump-
tion of AT III due to the coagulation activation. And
finally, vitamin D binding protein, as a novel biomarker
for MODS in different conditions, can be a possible target
for further validation in babesiosis.Conclusions
The search for new biomarkers for early detection, moni-
toring and prognosis of canine babesiosis is an active area
of interest. The objective in utilizing proteomic techniques
of this study was to identify differentially expressed protein
biomarkers in babesiosis. As a result, a number of differen-
tially expressed serum proteins involved in inflammation
mediated acute phase response (alpha-1-acid glycoprotein,
leucine-rich-alpha-2-glycoprotein, haptoglobin, hemopexin,
serotransferrin, alpha-2-HS-glycoprotein, albumin), com-
plement and coagulation cascades (AT III, CLU, C3, alpha-
2-antiplasmin), apolipoproteins (apoA-I and apoA-IV) and
vitamin D metabolism pathway were identified in dogs with
babesiosis. These results may provide possible serum bio-
marker candidates for clinical monitoring of babesiosis.
The major limitation of this study is insensitivity of 2-DE
gel methods used for proteome analysis. Thus, the deple-
tion of major proteins has been suggested to be a potential
strategy for enhancing detection sensitivity in serum. How-
ever, this study could serve as the basis for further prote-
omic investigations in canine babesiosis.Additional files
Additional file 1: List of proteins identified in serum of dogs with
B. canis canis at the day of admission. a) Number refer to protein
spots indicated in Figure 1b) Accesion number from NCBI Genbank
database for Canis lupus familiaris.
Additional file 2: List of proteins identified in serum of dogs with
B. canis canis on the first day. a) Number refer to protein spots
indicated in Figure 1b) Accesion number from NCBI Genbank database
for Canis lupus familiaris.
Additional file 3: List of proteins identified in serum of dogs with
B. canis canis on the 6th day. a) Number refer to protein spots
indicated in Figure 1b) Accesion number from NCBI Genbank database
for Canis lupus familiaris.
Additional file 4: List of proteins identified in serum of healthy
dogs. a) Number refer to protein spots indicated in Figure 1b) Accesion
number from NCBI Genbank database for Canis lupus familiaris.
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